FcγRIIa and FcγRIIIa polymorphisms in childhood primary immune thrombocytopenia: Implications for disease pathogenesis and outcome

Blood Coagulation and Fibrinolysis

Volumn 24, Issue 1, 2013, Pages 35-39

  Papagianni, Andromachi ^a   Economou, Marina ^a   Tragiannidis, Athanasios ^b   Karatza, Eliza ^a   Samarah, Fekri ^c   Gombakis, Nikolaos ^a   Athanassiadou Piperopoulou, Fani ^b   Vavatsi Christaki, Norma ^c   Athanassiou Metaxa, Miranda ^a  

^a Ippokration General Hospital   (Greece)

^b 2nd Paediatric Department   (Greece)

^c ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

Author keywords

childhood; Fc receptors; Fc RIIa; Fc RIIIa; immune thrombocytopenia; polymorphisms

Indexed keywords

ARGININE; FC RECEPTOR; FC RECEPTOR IIA; FC RECEPTOR IIIA; HISTIDINE; IMMUNOGLOBULIN; PHENYLALANINE; UNCLASSIFIED DRUG; VALINE;

ADOLESCENT; ARTICLE; BINDING AFFINITY; CHILD; CHILDHOOD DISEASE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIMARY IMMUNE THROMBOCYTOPENIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN FUNCTION; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 84871817709     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0b013e328359bc3b     Document Type: Article

References (21)

1. Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009; 113:2386-2393.
2. Crow AR, Lazarus AH. Role ofFcgamma receptors in the pathogenesis and treatment of idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol 2003; 25:S14-S18. (Pubitemid 37517912)
3. van der Pol W, van de Winkel JG. IgG receptor polymorphisms: risk factors for disease. Immunogenetics 1998; 48:222-232. (Pubitemid 28352188)
4. Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol 2001; 19:275-290. (Pubitemid 32368037)
5. Ericson SG, Coleman KD, Wardwell K, Baker S, Fanger MW, Guyre PM, et al. Monoclonal antibody 197 (anti-Fc gamma RI) infusion in a patient with immune thrombocytopenia purpura (ITP) results in down-modulation of Fc gamma RI on circulating monocytes. Br J Haematol 1996; 92:718-724. (Pubitemid 26078028)
6. Clarkson SB, Bussel JB, Kimberly RP, Valinsky JE, Nachman RL, Unkeless JC. Treatment of refractory immune thrombocytopenic purpura with an anti Fc gamma-receptor antibody. N Engl J Med 1986; 314:1236-1239. (Pubitemid 16106411)
7. Kurlander RJ, Hall J. Comparison of intravenous gamma globulin and a monoclonal anti-Fc receptor antibody as inhibitors of immune clearance in vivo in mice. J Clin Invest 1986; 77:2010-2018. (Pubitemid 16062658)
8. Song S, Crow AR, Freedman J, Lazarus AH. Monoclonal IgG can ameliorate immune thrombocytopenia in a murine model of ITP: an alternative to IVIG. Blood 2003; 101:3708-3713. (Pubitemid 36857963)
9. Teeling JL, Jansen-Hendriks T, Kuijpers TW, de Haas M, van de Winkel JG, Hack CE, Bleeker WK. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. Blood 2001; 98:1095-1099.
10. Parren PW, Warmerdam PA, Boeije LC, Arts J, Westerdaal NA, Vlug A, etal. On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2. J Clin Invest 1992; 90:1537-1546.
11. Warmerdam PA, van de Winkel JG, Vlug A, Westerdaal NA, Capel PJ. A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding. J Immunol 1991; 147:1338-1343.
12. Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M. Fc gammaRIIIa-158 V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 1997; 90:1109-1114. (Pubitemid 27314146)
13. Buchanan GR, Adix L. Grading of hemorrhage in children with idiopathic thrombocytopenic purpura. J Pediatr 2002; 141:683-688. (Pubitemid 35292768)
14. Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115:168-186.
15. Jiang XM, Arepally G, Poncz M, McKenzie SE. Rapid detection of the Fc gamma RIIA-H/R 131 ligand-binding polymorphism using an allele-specific restriction enzyme digestion (ASRED). J Immunol Methods 1996; 199:55-59. (Pubitemid 26392327)
16. Carcao MD, Blanchette VS, Wakefield CD, Stephens D, Ellis J, Matheson K, et al. Fcgamma receptor IIa and IIIa polymorphisms in childhood immune thrombocytopenic purpura. Br J Haematol 2003; 120:135-141. (Pubitemid 36056921)
17. van der Pol WL, Jansen MD, Sluiter WJ, van de Sluis B, Leppers-van de Straat FG, Kobayashi T, et al. Evidence for nonrandom distribution of Fcgamma receptor genotype combinations. Immunogenetics 2003; 55:240-246. (Pubitemid 36960517)
18. Wu J, Edberg JC, Redecha PB, Bansal V, Guyre PM, Coleman K, et al. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest 1997; 100:1059-1070. (Pubitemid 27386289)
19. Foster CB, Zhu S, Erichsen HC, Lehrnbecher T, Hart ES, Choi E, et al. Early Chronic ITP Study Group. Polymorphisms in inflammatory cytokines and Fcgamma receptors in childhood chronic immune thrombocytopenic purpura: a pilot study. Br J Haematol 2001; 113:596-599. (Pubitemid 32524376)
20. Fujimoto TT, Inoue M, Shimomura T, Fujimura K. Involvement of Fc gamma receptor polymorphism in the therapeutic response of idiopathic thrombocytopenic purpura. Br J Haematol 2001; 115:125-130. (Pubitemid 32995105)
21. Bryce A. IgGFc receptor polymorphisms inhuman disease: implications for intravenous immunoglobulin therapy. J Allergy Clin Immunol 2003; 111:697-703.